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Background/aim: Peritoneal sclerosis may be observed in varied manifestations. However, the most serious form is the encapsulated
peritoneal sclerosis. We researched the effect of rituximab on peritoneal fibrosis in an experimental rat model.
Materials and methods: Twenty-four Wistar Albino rats were divided into 4 equal groups. During weeks 0–3; group I received isotonic
saline (IS) solution, group II, group III, and group IV received chlorhexidine gluconate (CG) via intraperitoneal (i.p.) route. In the next
3 weeks nothing adminestred to both group I and group II but IS solution was adminestred to group III via i.p. route and 375 mg/m2/
week rituximab was applied intravenously on days 21, 28, and 35 to group IV. Fibrosis, peritoneal thickness, and inflammation were
evaluated. Immunohistochemical methods used for the detection of matrix MMP-2, TGF-β1, and VGEF expressions.
Results: The rituximab (group IV) had significantly lower fibrosis and peritoneal thickness scores than the group II and III (P < 0.001).
TGF-β1 and VEGF expressions were significantly lower in the rituximab group than in the group II and III (P < 0.001).
Conclusion: We found that rituximab had a significant effect on the peritoneal thickness, total fibrosis, TGF-β1 and VGEF scores which
were induced by CG.
Key words: Rituximab, encapsulated peritoneal sclerosis, matrix metalloproteinase-2, transforming growth factor-beta, vascular
endothelial growth factor

1. Introduction
Peritoneal sclerosis may be observed in varied
manifestations. However, the most serious form is
encapsulated peritoneal sclerosis (EPS). EPS has a low
prevalence of up to 3%, but it is associated with a high
mortality rate of up to 51% in patients undergoing
peritoneal dialysis (PD). Therefore, EPS is of major
concern to nephrologists []. The characteristic feature of
EPS is extreme sclerosis of the peritoneal membrane, which
covers and constricts the intestines []. Although several
studies have examined EPS, the exact pathophysiology of
EPS remains unclear. The triggering factors involved in
the pathogenesis of systemic fibrosis and EPS were M2type macrophages, CD4+T cells [], B cells [], the matrix
metalloproteinase (MMP) family, particularly MMP-2 [,],
and transforming growth factor-beta 1 (TGF- β1) [].
Nishino et al. reported that T and B lymphocytes had
important roles in the process of peritoneal fibrosis in a
mouse peritoneal fibrosis model []. However, Habib et
al. reported that there were no CD20 and CD15 positive
cells in the biopsies of a subgroup of patients with EPS [].

Conversely, Bosello reported the potential role of B cells in
tissue fibrosis in some experimental models, thus, targeting
B cells could be one method of reducing extracellular
matrix deposition and lowering the inflammatory status
[4]. Research has also shown the effect of the anti-B cell
monoclonal antibody, rituximab, in the treatment of
diseases involving fibrotic processes [4,,].
A variety of therapeutic approaches to EPS including
surgical and medical options have been reported []. In
recent studies, the effects of various immunosuppressive
drugs such as prednisone, azathioprine, mycophenolate
mofetil (MMF), and sirolimus have been investigated [,].
We reported the effect of the T cell blocker abatacept in
the treatment of EPS in our previous study []. However,
to our knowledge, no data on the effect of the anti-CD
20+ antibody, rituximab, in EPS models are available.
Rituximab (MabThera/Rituxan), a chimeric murine/
human monoclonal antibody, binds specifically to the
transmembrane antigen CD20 on B cells [].
The aim of this study was to investigate the effect
of rituximab in an experimental rat model in which
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chlorhexidine gluconate was used to induce peritoneal
fibrosis.
2. Materials and methods
The Institutional Animal Use and Care Committee of
the Ankara Education and Research Hospital approved
the study protocol, and the study was performed in
accordance with the National Institutes of Health
guidelines. Twenty-four female Wistar Albino rats with a
mean weight of 180–200 g were selected for the study. The
rats were randomly divided into 4 equal groups and kept
at room temperature (24°C) in a 12-h light/dark cycle in
polycarbonate cages and fed a standard laboratory diet for
42 days. The EPS model was performed as described by
Ishii et al. [].
During weeks 0–3, group I (control group) received
isotonic saline (IS) (2 mL/day) solution intraperitoneally
(i.p.), group II (CG group), group III (CG + IS group),
and group IV (rituximab group) received chlorhexidine
gluconate (CG) solution (2 mL of 0.1% CG and 15%
ethanol dissolved in IS) via the i.p. route. In the next 3
weeks, nothing was administered to both group I and
group II, but IS solution was administered to group III
and 375 mg/m2/week rituximab (MabThera) (diluted
with saline to 1mg/mL) was given intravenously on days
21, 28, and 35 to group IV. A 23-G needle was used for
all intra abdominal injections. In order to eliminate the
effects of recurrent injections to the peritoneum, daily
injections were administered to the lower part of the
abdominal peritoneal cavity, whereas for the pathologic
investigations, the right-left upper quadrant of the parietal
peritoneum was preferred.
2.1. Histologic examination
Ketamine and xylazine were used for anesthesia, and on the
42nd day of the study, all rats were euthanized via cervical
dislocation. Following laparotomy, parietal peritoneal
samples were collected from the right-left upper quadrant
of the abdomen. The peritoneal membrane samples were
fixed in 4% formalin and embedded in paraffin wax.
Paraffin blocks were cut into 5-μm-thick sections and
stained using hematoxylin–eosin (HE) and Masson’s
trichrome (MT). A pathologist, who was blinded to the
treatment groups, examined the samples. The peritoneal
thickness, fibrosis, degree of inflammation; and TGF-β1,
MMP-2, VGEF scores were investigated in all groups. An
ocular micrometer was used to measure the peritoneal
thickness. Measurements were performed for 3 areas,
and the mean value was considered as the peritoneum
thickness.
The pathologist semiquantitatively scored the degree of
fibrosis in MT-stained sections on a 5-point scale: score 0
= none; 1 = low; 2 = mild; 3 = moderate; 4= high moderate;
and 5 = severe. The scoring system for 3 parameters that
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described the fibrosis score was as follows: the subserosal
fibrotic matrix (on a 2-point scale: 0 = none; 1 = mild;
and 2 = marked), subserosal large collagen fibers (on a
scale of 0–1: 0 = absent and 1 = present), and subserosal
fibrotic proliferation (on a 2-pointscale: 0 = none; 1
= mild, and 2 = intense) [16]. The fibrosis score was
calculated by summing the subserosal large collagen
fibers, subserosal fibrotic proliferation, and subserosal
fibrotic matrix scores. The degree of inflammation in HEstained sections was scaled as score 0 = none; 1 = mild
inflammation (presence of few scattered inflammatory
cells); 2 = moderate inflammation (small groups of
inflammatory cells in high-power fields); and score 3 =
severe inflammation (many inflammatory cells in either
a diffuse pattern or large groups). Vasculopathy was
evaluated as described by Williams et al. [].
2.2. Immunohistochemical staining
Anti-MMP-2, anti-TGF-β1, and anti-VGEF antibodies
were used for the immunostaining of MMP-2, TGF-β1,
and VGEF using the Leica Bond-Max automatic
immunostainer
(Novocastra-Leica
Microsystems,
Newcastle upon Tyne, UK). Deparaffinized sections
were treated with 0.3% hydrogen peroxide (H2O2) and
blocked with 0.5% bovine serum albumin for 10 min
at room temperature. The sections were incubated with
anti-MMP-2 antibody (mouse monoclonal, 1:50 diluted),
anti-TGF-β1 antibody (mouse monoclonal, 1:100
diluted), and anti-VGEF antibody (mouse monoclonal,
1:200 diluted) for 20 minutes, followed by a further
incubation with 0.1% H2O2 for 10 minutes. Hematoxylin
was used as a counterstain. Positive staining was scored
in a semiquantitative manner from 0 to 4:0 = almost no
staining; 1 = staining < 25%; 2 = staining 25–50%; 3 =
staining 50–75 %; and 4 = staining > 75% [].
2.3. Statistical analyses
The SPSS statistical package, version 24.0 (IBM Corp.,
Armonk, NY, USA), for Windows was used for the
statistical analyses. Shapiro–Wilk test was performed
to determine the normality of distribution. Descriptive
statistics were presented as mean ± SEM for normally
distributed variables and as median (range) for
nonnormally distributed variables. The significance of
the difference of the means between the groups were
evaluated by the one-way ANOVA test for peritoneal
thickness. If there was a significant difference between the
groups, a post-hoc analysis was performed to determine
which group had a different result. Comparison of
nonnormal distributed variables (Inflammation, Total
Fibrosis, MMP 2, TGF beta, and VEGF scores) was
made by Kruskal–Wallis test. Kruskal–Wallis multiple
comparison test was performed to the significance of
pairwise differences using Bonferroni correction to
adjust for multiple comparisons.
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3. Results
Throughout the study all the animals have stable weight
and health, and rituximab was well tolerated without
an adverse event. The histopathological findings of the
peritoneum are demonstrated in Table. Morphological
parameters, including peritoneal thickness, inflammation,
and fibrosis scores of the group II were significantly
different from those of the group I (1761.5 ± 834.9
μm vs. 261.7 ± 104.5 μm, 1.5 (IR:1.75) vs. 0 (IR:0.75)
and 4 (IR:1.75) vs. 0.5 (IR:1), respectively; P < 0.05).
Significantly better histopathological parameters in terms
of peritoneal thickness and fibrosis scores were observed
in the rituximab group than in the group III (334.8 ±
126.1 vs. 2518.1 ± 1401 μm and 1 (IR:0.75) vs. 4 (IR:2),
respectively; P < 0.05). However, the inflammation score
in group IV was not statistically different from group II
and III [1 (IR:1) vs. 1.5 (IR:1.75) and 1 (IR:1) respectively;
P > 0.05]. The group II and III had similar morphological
parameter results (Table). There was no difference in terms
of vascular scores between groups. Parietal peritoneal
tissue samples of all groups were assessed using 2 different
histological methods, HE staining (Figure 1) and MT
staining (Figure 2). MMP-2, TGF-β1, and VGEF scores
of parietal peritoneum are also summarized in Table. The
group II and III had higher tissue MMP-2, TGF-β1, and
VGEF scores than the group I. The TGF-β1 and VGEF
scores level were significantly lower in group IV than
group III. The immunohistochemical staining of parietal
peritoneal tissue samples of all groups with MMP-2,
TGF-β1, and VGEF antibodies are shown in Figures 3, 4,
and 5.

score in the rituximab group was lower than in group II,
the difference was not statistically significant. However,
the fibrotic marker TGF-β1, as well as the vascular factor
VEGF were significantly lower in the rituximab group
than group III.
EPS could be accepted as an orphan disease because
its pathogenesis and treatment remains unclear. Bowel
rest with total parenteral nutrition, surgical interventions,
and a few drugs that have been used in patients have been
proposed for EPS treatment [,]. Immunosuppressive drugs,
such as everolimus, MMF, abatacept, and thalidomide, have
been tested on experimental rat models and demonstrated
to be effective in EPS treatment [,,10,].
Several studies have reported that B cells play a
pathogenic role in diseases with fibrotic processes [,,,,].
Activated B cells and macrophages might secrete high
amounts of TGF-β, which have important roles in the
pathogenesis of fibrosis []. Nishino et al. [8] investigated
the role of lymphocytes in the process of peritoneal fibrosis
in an experimental rat model and showed that the thicker
submesothelial compact zone had a higher amount of B
lymphocytes and macrophages than those observed in
control immune deficient and wild-type mice.
However, the effect of immune modulator agents that
block B cells in EPS treatment remain unknown. To our
knowledge, this is the first study that investigate the effect
of rituximab on peritoneal fibrosis. Rituximab significantly
reduced peritoneal thickness and fibrosis in our study.
Peritoneal thickness, fibrosis scores, as well as the TGF-β1
and VGEF scores were significantly lower in group IV than
in group III. When compared with our previous study
with abatacept, rituximab was more effective in improving
peritoneal thickness and fibrosis. However, abatacept was
more effective in improving the inflammation score [15].
Studies with sirolimus and everolimus showed similar
results to rituximab; each decreased peritoneal thickness and

4. Discussion
We demonstrated the effectiveness of rituximab in
lowering fibrosis scores and peritoneal thickness in an
experimental rat model. Although the inflammation

Table. Histopathologic parameters of the peritoneum and MMP-2, TGF-β, and VGEF results in each group.
Mean ± SD
Median (IR)

Control
(Group I)

CG
(Group II)

CG+SF
(Group III)

CG+Rituximab
(Group IV)

P

Peritoneal thickness (μm)

261.7 ± 104.5

1761.5 ± 834.9a

2518.1 ± 1401.3a

334.8 ± 126.1b,c

<0.001

Inflammation score
(0–3 scale)

0 (0.75)

1.5 (1.75)a

1(1)a

1 (1)

0.008

Total Fibrosis score
(0–5 scale)

0.5 (1)

4 (1.75)a

4 (2)a

1 (0.75)b,c

<0.001

MMP 2 score

0 (1)

2 (1.75 )

2 (2)

1 (1)

0.001

TGF beta score

0 (1)

1.5 (1)

2.5 (1.75)a

0.5 (1)b

VEGF score

0 (0.75)

1 (1)

2 (1)

0 (0.75)

a

a

a

0.001
b

0.001

P < 0.05 as compared with control bP < 0.05 as compared with CG+SF cP < 0.05 as compared with CG

a
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Figure 1. HE staining of parietal peritoneal tissue samples of all groups (× 100). (a: Group I, b: Group II, c: Group III, d:Group IV)

Figure 2. Masson’s trichrome staining of the parietal peritoneal tissue samples of all groups (× 100). (a: Group I, b: Group II, c: Group
III, d:Group IV)
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Figure 3. Immunohistochemical analysis of MMP-2 expressions in the peritoneal tissue samples of all groups (× 10 ihk). (a: Group I, b:
Group II, c: Group III, d:Group IV)

Figure 4. Immunohistochemical analysis of the TGF-β1 expression in the peritoneal tissue samples of all the groups (× 10 ihk). (a:
Group I, b: Group II, c: Group III, d:Group IV)
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Figure 5. Immunohistochemical analysis of theVGEF expression in the peritoneal tissue samples of all groups (× 10 ihk). (a: Group I,
b: Group II, c: Group III, d:Group IV)

fibrosis but had not significant effect on inflammation scores
[,]. Huddam et al. reported that MMF had a significant effect
on fibrosis, peritoneal thickness, and inflammation scores.
However, the MMP-2 level increased after MMF treatment
in their study [23]. Another study showed that after MMF
treatment, MMP-2 and TGF-β1 gene expressions decreased
significantly []. Moreover, sirolimus showed no significant
effect on MMP-2 levels [31].
MMF and sunitinib treatment have a significant impact
on dialysate TGF-β1 levels as compared with the resting
EPS rat model [,]. The tissue immunohistochemical score
of TGF-β1 significantly decreased after the rituximab
treatment in our study. This is the first study to investigate
the tissue immunohistochemical score of VGEF. The
VGEF score was significantly lower in group IV than in
group III.

Consequently, we demonstrated that rituximab might
reduce fibrosis and peritoneal thickness, and TGF-β1,
VGEF scores in an EPS rat model. For evidence-based
treatment of EPS, further larger and detailed studies are
required to show the effectiveness of rituximab.
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